



Research Progress in Stem Cells and Regenerative Medicine

Guest Editor:

Prof. Dr. Naoki Yamamoto

Research Promotion and Support
Headquarters, Fujita Health
University, Toyoake 470-1192,
Aichi, Japan

Deadline for manuscript
submissions:

31 October 2024

Message from the Guest Editor

ES cells, iPS cells, and tissue stem cells are central cells in regenerative medicine. Recently, in the clinical application of regenerative medicine, attention has not only been focused on cells, but also on tissue regeneration after being secreted from cells. In the area of drug discovery, drug screening using iPS cells and immortalized cells has been widely reported. On the other hand, cancer stem cells also have a significant impact on cancer recurrence and metastasis. Cancer stem cells and mature cancer cells differ significantly in the metabolism of drugs (such as anticancer drugs).

This Special Issue invites submissions (reviews and originals) on a wide range of research studies, including on cell-based analysis, under the theme 'Regenerative Cell Engineering'.

This Special Issue includes, but is not limited to, the following:

- Regenerative medicine (ES cells, iPS cells, and tissue stem cells);
- Cancer therapy (cancer stem cells, cancer-associated fibroblasts, and cancer cell markers);
- Culture methods for tissue and cancer stem cells (2D culture, organoid culture, and xenografts);
- Cell-related drug screening;
- Alternative methods to animal experiments using cells.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Anthony Guiseppi-Elie

Department of Biomedical
Engineering, Texas A&M
University, College Station, TX
77843, USA

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Bioengineering* (ISSN 2306-5354). *Bioengineering* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. *Bioengineering* provides an advanced forum for the science and technology of bioengineering. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, Inspec, and other databases.

Journal Rank: JCR - Q2 (*Engineering, Biomedical*)

Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.6 days after submission; acceptance to publication is undertaken in 3.1 days (median values for papers published in this journal in the first half of 2024).

Contact Us

Bioengineering Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/bioengineering
bioengineering@mdpi.com
[X@Bioeng_MDPI](https://twitter.com/Bioeng_MDPI)